Tocilizumab: all 334 studies that test it
Page 3 of 4. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.
- A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal FibrosisStatus unknownNCT04762784Phase 4
- TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center ExperienceCompletedNCT04730323Phase 4
- Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 ProteinsCompletedNCT04690920Not applicable
- A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.Status unknownNCT04688021Phase 2
- Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- ImmunotherapyTerminatedNCT04652258Phase 2
- Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R BlockadeCompletedNCT04616235Not applicable
- Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 InfectionCompletedNCT04600141Phase 3
- Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu ArteritisStatus unknownNCT04564001Phase 2
- Tocilizumab in COVID-19 Lahore General HospitalStatus unknownNCT04560205Phase 1
- Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab TherapyActive, not recruitingNCT04554771Phase 2
- Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)CompletedNCT04547062Phase 1
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingNCT04524871Phase 1/2
- Toclizumam Versus Dexamethasone in Severe Covid-19 CasesCompletedNCT04519385Not applicable
- Investigational Treatments for COVID-19 in Tertiary Care Hospital of PakistanCompletedNCT04492501Not applicable
- Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19CompletedNCT04476979Phase 2
- Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 PneumoniaCompletedNCT04445272Phase 2
- Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)TerminatedNCT04435717Phase 2
- A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseStatus unknownNCT04424056Phase 3
- Tocilizumab in Coronavirus-19 Positive PatientsStatus unknownNCT04423042Phase 3
- Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTSTerminatedNCT04412772Phase 3
- Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory MarkersTerminatedNCT04403685Phase 3
- Ultra Low Doses of Therapy With Radiation Applicated to COVID-19SuspendedNCT04394182Not applicable
- The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary HyperinflammationStatus unknownNCT04377750Phase 4
- Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19TerminatedNCT04377503Phase 2
- Tocilizumab Treatment in Patients With COVID-19Active, not recruitingNCT04363853Phase 2
- Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)WithdrawnNCT04361552Phase 3
- Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in TunisiaStatus unknownNCT04361032Phase 3
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolCompletedNCT04349410Phase 2/3
- A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19CompletedNCT04347031Phase 2/3
- Efficacy of Early Administration of Tocilizumab in COVID-19 PatientsTerminatedNCT04346355Phase 2
- Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of ProgressionStatus unknownNCT04345445Phase 3
- Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ DysfunctionCompletedNCT04339712Phase 2
- Checkpoint Blockade in COVID-19 PandemicTerminatedNCT04335305Phase 2
- Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)TerminatedNCT04335071Phase 2
- Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)Status unknownNCT04332094Phase 2
- Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory FailureTerminatedNCT04322773Phase 2
- Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsActive, not recruitingNCT04321993Phase 2
- Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)Status unknownNCT04317092Phase 2
- Tocilizumab for SARS-CoV2 (COVID-19) Severe PneumonitisStatus unknownNCT04315480Phase 2
- Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerTerminatedNCT04258150Phase 2
- Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host DiseaseTerminatedNCT04070781Phase 1
- Tocilizumab in Children With ACPActive, not recruitingNCT03970226Early Phase 1
- IL-6 Regulation of Substrate Metabolism and Influence of ObesityCompletedNCT03967691Not applicable
- Cell Therapy for Immunomodulation in Kidney TransplantationActive, not recruitingNCT03867617Phase 1/2
- IL-6 Inhibition for Modulating Inflammation After Cardiac ArrestCompletedNCT03863015Phase 2
- Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateCompletedNCT03830203Phase 3
- Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive DisorderSuspendedNCT03787290Phase 2
- Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid ArthritisStatus unknownNCT03781310Phase 4
- Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and TocilizumabCompletedNCT03745586Phase 1/2
- Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
- Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy SubjectsCompletedNCT03606876Phase 1
- Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease MechanismsCompletedNCT03601611Not applicable
- Tocilizumab for the Treatment of Refractory Behcet's UveitisTerminatedNCT03554161Phase 2
- Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical TransplantationCompletedNCT03533101Phase 1/2
- Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy VolunteersCompletedNCT03522012Phase 1
- CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2
- Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma SurgeryTerminatedNCT03353259Phase 2/3
- Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum DisordersCompletedNCT03350633Phase 2/3
- A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT03301883Phase 4
- Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456CompletedNCT03282851Phase 1
- A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)CompletedNCT03263715Phase 3
- Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.Status unknownNCT03244709Phase 4
- An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)CompletedNCT03202368Phase 3
- An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) TherapyCompletedNCT03155347Phase 3
- Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabCompletedNCT03135171Phase 1
- Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationTerminatedNCT03100253Phase 4
- A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSDCompletedNCT03062579Phase 1/2
- Tocilizumab in Patients With Schnitzler's SyndromeCompletedNCT03046381Phase 2
- ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI TrialCompletedNCT03004703Phase 2
- Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)WithdrawnNCT02997956Phase 1/2
- Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory UveitisCompletedNCT02929251Phase 2
- Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORECompletedNCT02908217Phase 3
- Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release SyndromeCompletedNCT02906371Phase 1
- Ectopic Adipose Tissue, Exercise Training and IL-6CompletedNCT02901496Not applicable
- Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab TherapyCompletedNCT02843789Phase 4
- Treatment Tapering in JIA With Inactive DiseaseCompletedNCT02840175Phase 3
- Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid ArthritisStatus unknownNCT02837146Phase 3
- Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer PatientsCompletedNCT02767557Phase 2
- Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid ArthritisCompletedNCT02765074Phase 4
- A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy VolunteersCompletedNCT02678988Phase 1
- A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial HypertensionCompletedNCT02676947Phase 2
- Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 StudyWithdrawnNCT02511067Phase 2
- Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand OsteoarthritisCompletedNCT02477059Phase 3
- Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease ActivityStatus unknownNCT02466581Phase 4
- Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
- A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and ComorbiditiesTerminatedNCT02336048Phase 1
- Tocilizumab for Chronic Graft-versus-Host Disease TreatmentWithdrawnNCT02174263Phase 2
- Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic ArthritisCompletedNCT02165345Phase 1
- Efficacy and Tolerance of Tocilizumab In Takayasu ArteritisCompletedNCT02101333Phase 3
- Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid ArthritisStatus unknownNCT02087696Phase 4
- Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02057770Phase 1
- A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.CompletedNCT02011334Phase 3
- Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)WithdrawnNCT02007239Phase 2
- A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic ArthritisCompletedNCT01904292Phase 1
- A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDsWithdrawnNCT01878318Phase 4
- TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONECompletedNCT01791842Phase 2
- Efficacy of Tocilizumab in Primary Sjögren's Syndrome.CompletedNCT01782235Phase 2/3
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926CompletedNCT01730456Phase 3
- An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 StudyCompletedNCT01727986Phase 3
- Pilot Study of Tocilizumab in Patients With Erdheim-Chester DiseaseTerminatedNCT01727206Phase 2